Seborrheic Dermatitis
Conditions
Interventions
test group:Continuous use of Bioderma Sensibio Soothing Milk for 4 weeks followed by a 2-week discontinuation period
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Study participants have read, understood, and signed the informed consent form prior to the study; 2. Study participants are Chinese men and women aged between 18 and 60 years old; 3. Diagnosed with seborrheic dermatitis in accordance with the Expert Consensus on the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Seborrheic Dermatitis (2024 Edition), with a score ranging from 3 to 9 on the 16-item seborrheic dermatitis scale; 4. Study participants are able to comply with the trial requirements and participate in the trial as instructed; 5. Study participants agree not to use any new cosmetics, toiletries, or personal skincare products on the trial site during the trial period, except for the trial samples.
Exclusion criteria
Exclusion criteria: 1. Study participants who are in the lactation or pregnancy period, or those planning to become pregnant during the trial period (for females only); 2..Participants with severe facial skin infections, damage, or exudation; 3. Participants with a serious history of skin diseases or currently suffering from unhealed skin conditions that, in the opinion of the doctor or researcher, may interfere with the conduct of the trial, affect the trial results, or increase the risk of adverse reactions (e.g., eczema, psoriasis, rosacea, suspicious lesions, moderate to severe acne, rashes, skin damage, scars, tattoos, sunburn, etc.); 4. Participants with other uncontrolled severe systemic diseases; 5. Participants requiring concurrent use of other investigational drugs; 6. Participants with a history of malignancy, HIV infection, and/or autoimmune diseases; 7. Participants with a history of angioedema and/or anaphylactic shock; 8. Participants who have participated in other drug clinical trials within the 3 months prior to screening evaluation; 9. Participants who have participated in other similar cosmetic clinical trials within the 1 month prior to screening evaluation; 10. Other situations deemed unsuitable for participation in the clinical study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| erythema score;scales score;pruritus score; | — |
Secondary
| Measure | Time frame |
|---|---|
| proportion of red area;SEsc;SEsm;a value;Oil content;Superficial skin blood perfusion volume;Transepidermal water loss (TEWL) rate of the skin;Skin microbiome 16S and ITS sequencing;1L-1a;1L-6;1L-8;TNF-a; | — |
Countries
China
Contacts
Public ContactYihong Qian
Shanghai Skin Disease Hospital
Outcome results
None listed